Sutro Biopharma STRO Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $99.61M-2.8% | $102.48M-3.0% | $105.65M+1.1% | $104.47M+57.3% | $66.43M+7.1% | ||
| $151.37M-9.0% | $166.42M-17.1% | $200.81M-10.0% | $223.07M-9.6% | $246.76M-2.1% | ||
| $35.33M-13.9% | $41.02M-0.9% | $41.39M-11.9% | $46.98M-4.1% | $49.01M+1.1% | ||
| $32.41M-39.3% | $53.42M— | —— | —— | —— | ||
| $219.12M-16.0% | $260.85M-10.4% | $291.22M-5.9% | $309.51M-2.3% | $316.81M+5.4% | ||
| $219.12M-16.0% | $260.85M-10.4% | $291.22M-5.9% | $309.51M-2.3% | $316.81M+5.4% | ||
| -$119.51M+24.5% | -$158.37M+14.7% | -$185.58M+9.5% | -$205.04M+18.1% | -$250.38M-5.0% | ||
| -120%+34.5pp | -154.5%+21.1pp | -175.7%+20.6pp | -196.3%+181pp | -376.9%+7.5pp | ||
| -$153.72M+19.6% | -$191.18M+10.8% | -$214.42M-3.9% | -$206.35M+15.0% | -$242.85M-7.9% | ||
| -$115K-23.7% | -$93K-104% | $2.34M0.0% | $2.34M-1.1% | $2.37M+0.3% | ||
| -$153.6M+19.6% | -$191.09M+11.8% | -$216.77M-3.9% | -$208.7M+14.9% | -$245.22M-7.8% | ||
| -154.2%+32.2pp | -186.5%+18.7pp | -205.2%-5.4pp | -199.8%+169pp | -369.1%-2.5pp | ||
| -$24.53+20.0% | -$30.67+17.6% | -$37.22-0.2% | -$37.14+1.2% | -$37.59-29.2% | ||
| -$24.53+20.0% | -$30.67+17.6% | -$37.22-0.2% | -$37.14+1.2% | -$37.59-29.2% | ||
| 191M+2.5% | 186.3M+0.4% | 185.6M+1.5% | 182.7M+1.9% | 179.4M-22.8% | ||
| 191M+2.5% | 186.3M+0.4% | 185.6M+1.5% | 182.7M+1.9% | 179.4M-22.8% | ||
| -$3.57M+7.3% | -$3.86M-185% | $4.51M-83.5% | $27.42M+2.7% | $26.7M+3.6% | ||
| $7.7M-16.8% | $9.25M-25.9% | $12.48M-18.7% | $15.34M-13.5% | $17.74M-4.9% | ||
| $38.33M+0.3% | $38.21M+2.3% | $37.35M+4.9% | $35.59M+7.1% | $33.23M+7.0% | ||
| $99.61M-2.8% | $102.48M-3.0% | $105.65M+1.1% | $104.47M+57.3% | $66.43M+7.1% | ||
| -$119.51M+24.5% | -$158.37M+14.7% | -$185.58M+9.5% | -$205.04M+18.1% | -$250.38M-5.0% | ||
| -$112.81M+25.3% | -$151.04M+15.1% | -$178.01M+9.9% | -$197.57M+18.7% | -$243.02M-5.1% | ||
| -$112.81M+25.3% | -$151.04M+15.1% | -$178.01M+9.9% | -$197.57M+18.7% | -$243.02M-5.1% | ||
| -113.3%+34.1pp | -147.4%+21.1pp | -168.5%+20.6pp | -189.1%+177pp | -365.8%+6.9pp | ||
| -$119.51M+24.5% | -$158.37M+14.7% | -$185.58M+9.5% | -$205.04M+18.1% | -$250.38M-5.0% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Sutro Biopharma's revenue?
- Sutro Biopharma (STRO) generated $99.6M in revenue over the trailing twelve months, up 49.9% year over year.
- Is Sutro Biopharma profitable?
- Sutro Biopharma is not currently profitable: it reported a net loss of $153.6M over the trailing twelve months, a -154.2% net margin.
- What is Sutro Biopharma's earnings per share?
- Sutro Biopharma's diluted EPS over the trailing twelve months is $-24.53.
- Where does Sutro Biopharma's income statement data come from?
- Every line is extracted from Sutro Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
